Novartis AG
Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
Last updated:
Abstract:
A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.
Status:
Grant
Type:
Utility
Filling date:
5 Jan 2018
Issue date:
8 Sep 2020